Silver Book Fact

A recent study showed that memantine, a medicine approved to treat moderate-to-severe Alzheimer’s, significantly slows cognitive decline and reduces the need for caregiving by 45.8 hours per month.

Reisberg, Barry, Rachelle Doody, Albrecht Stöffler, Frederick Schmitt, Steven Ferris, and Hans Jörg Möbius. Memantine in Moderate-to-Severe Alzheimer’s Disease. New England Journal of Medicine. 2003; 348(14): 1333-41. http://content.nejm.org/cgi/content/abstract/348/14/1333?hits=20&where=fulltext&andorexactfulltext=and&searchterm=reisberg&sortspec=Score%2Bdesc%2BPUBDATE_SORTDATE%2Bdesc&excludeflag=TWEEK_element&searchid=1&FIRSTINDEX=0&resourcetype=HWCIT

Reference

Title
Memantine in Moderate-to-Severe Alzheimer’s Disease
Publication
New England Journal of Medicine
Publication Date
2003
Authors
Reisberg, Barry, Rachelle Doody, Albrecht Stöffler, Frederick Schmitt, Steven Ferris, and Hans Jörg Möbius
Volume & Issue
Volume 348, Issue 14
Pages
1333-41
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Medicines Allow Patients to Remain Independent Longer: New Alzheimer’s medicine delays need for costly home care  
  • Recent studies suggest that a low-fat diet which is rich in fruits and vegetables may support brain health. Other studies suggest that remaining socially active and intellectually engaged may also…  
  • The present value QUALY gains associated with a new drug that by 2010 could delay disease onset by 1, 3, and 5 years. The dollar value estimates range from approximately…  
  • Americans Age 65 and Older with Alzheimer’s Disease, 2010–2050  
  • Valuing a QALY at $175,000, new drugs that would produce a 5-year delay in Alzheimer’s disease onset for all new cases between 2010 and 2050 would yield a benefit of…